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Letters to the Editorhave demonstrated that genetic testing
is a useful tool for identifying a high-
risk population with a systemic in-
flammatory response syndrome after
cardiopulmonary bypass (CPB), we
would temper the assumption that
‘‘IL-6 and IL-10 now can be consid-
ered as the master predictive control
mediators of the post-CPB inflamma-
tory response’’ because of the multi-
plicity of the intermingled pathways
involved in that response2 and our
obvious inability to explore the ge-
netic determinants of all of them. Fur-
ther clinical investigations with larger
cohorts are clearly needed to pre-
cisely identify the specific contribu-
tion of interleukin-6 and -10 to each
of the clinical complications compos-
ing our clinical end point and to
unravel potential other mediators
that could also modulate the CPB-
induced inflammatory response, such
as chemokines that are currently un-
der investigation andmay be potential
therapeutic targets in the prevention
of systemic inflammatory response
syndrome.3
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WITH BRONCHOALVEOLAR
FEATURES: A POPULATION-
BASED EVALUATION OF THE
EXTENT OF RESECTION IN
BRONCHOALVEOLAR CELL
CARCINOMA
To the Editor:
The article by Whitson and
colleagues1 in the March 2012 issue
has what appears to be an error that
would benefit from clarification.
In the Methods section of their
article, they state that the time period
of interest for the evaluation of overall
and cancer-specific survival is from
1988 to 2007. In the first analysis they
compare those patients undergoing lo-
bectomy with those undergoing an un-
specified sublobar resection. They then
undertake a second analysis of those
patients undergoing specific types of
sublobar resection (wedge and seg-
mentectomy). To undertake this second
analysis, they state that only data from
1998 to 2007 are included as the neces-
sary information is only available in
patients undergoing surgery after 1998.
However, on inspection of their ta-
bles and figures it appears that in
both sets of analysis there are 5532 pa-
tients undergoing lobectomy. It cannot
be the case that there were 5532 lobec-
tomies from 1988 to 2007 and 5532
patients undergoing lobectomy from
1998 to 2007. It appears that their
analysis included patients undergoing
lobectomy from 1988 to 2007 and
those undergoing sublobar resection
from 1997 to 2007, that is, the 2
groups are not contemporaneous.
Is this an error? If not an error, how
do the authors justify this analysis
as these 2 populations are not
comparable?
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We thank Dr Srinathan for his
thoughtful review of our article. His
review has raised a valid question re-
garding the analysis. It would seem
that our description of the dataset
used was not as clear as we had
intended, and we offer this
clarification.
We limited our analysis to data col-
lected from January 1, 1988 (the year
Surveillance, Epidemiology, and End-
Results [SEER] registries began col-
lecting American Joint Committee
on Cancer staging data), through De-
cember 31, 2007. Because the SEER
registries did not differentiate be-
tween the various types of sublobar re-
sections (ie, wedge resections and
segmentectomies) until 1998, our sur-
vival analysis for wedge resections
and segmentectomies is limited to
data obtained from January 1, 1998,
through December 31, 2007. The pub-
lished graphs and tables display data
comparing survivals after wedge re-
section and segmentectomy (1998
through 2007) with survivals after lo-
bectomy (1988 through 2007).1
When we limited our analysis (for
all groups) to data obtained from Jan-
uary 1, 1998, through December 31,
2007, our results were unchanged.
By Kaplan-Meier analysis, we
noted significantly better overall
(P < .0001) and cancer-specific
survivals (P<.0001) after lobectomy
(n ¼ 3846) and segmentectomy
(n ¼ 152) as compared with wedge
resections (n ¼ 768). There was no
significant difference between the sur-
vivals of patients who underwent lo-
bectomies as compared with those
who underwent segmentectomies.
After adjusting for potential con-
founding covariates (using the same
Cox proportional hazards regression2
Letters to the Editormodel displayed in Table 3 of the pub-
lished article1), our results were
unchanged. Patients who underwent
lobectomy (adjusted hazard ratio
[aHR], 0.53; 95% confidence interval
[95% CI], 0.46-0.61) and segmentec-
tomy (aHR, 0.60; 95% CI, 0.43-0.83)
had significantly more favorable all-
cause mortality rates as compared
with patientswho underwentwedge re-
section. Similarly, patients who under-
went lobectomy (aHR, 0.48; 95% CI,
0.41-0.56) and segmentectomy (aHR,
0.52; 95% CI, 0.35-0.77) had signifi-
cantly more favorable cancer-specific
rates as compared with patients who
underwent wedge resection. There
was no significant difference in all-The Journalcause or cancer-specific mortality rates
between patients who underwent lo-
bectomies and patients who underwent
segmentectomies.
We appreciate Dr Srinathan’s raising
this point for explanation in our analy-
sis, and we thank the Editor for the op-
portunity to clarify our methodology
and the intent behind it.We had thought
that we had conveyed our analysis
clearly in the article; apparently, this
was not the case. We hope that this let-
ter elucidates our intent and analysis.
Our results indicate thatmore favorable
survivals are achieved after an ana-
tomic resection (ie, segmentectomy or
lobectomy) than after a nonanatomic
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